SPDR S&P World ex-US ETF
Teva Has a Targeted Strategy to Expand in Major Growth Markets
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
Teva’s Commercial Strategy May Be Successful across Europe
Teva Pharmaceutical (TEVA) currently operates in three types of markets in the European Union.
How Is Teva Aiming to Lead the Abuse-Deterrent Opioid Segment?
Teva Pharmaceutical Industries (TEVA) expects Vantrela, an abuse-deterrent opioid, to be approved by the FDA in 2016.